BaraschACunha-CruzJCurroFHujoelPSungAVenaD. (2011). Risk factors for osteonecrosis of the jaws: a dental Practice-based Research Network case-control study. J Dent Res90:439-444.
2.
BrownJEBarriosCHDielIJFaconTFizaziKIbrahimT. (2010). Incidence and outcomes of osteonecrosis of the jaw from an integrated analysis of three pivotal randomized double-blind, double-dummy phase 3 trials comparing denosumab and zoledronic acid for treatment of bone metastases in advanced cancer patients or myeloma. Presented at the Cancer and Bone Society 10th International Conference, Sheffield, UK, Sept. 22-25, 2010.
3.
CheungASeemanE (2010). Teriparatide therapy for alendronate-associated osteonecrosis of the jaw. New Engl J Med363:2473-2474.
4.
DollRHillAB (1950). Smoking and carcinoma of the lung. Br Med J2:739-748.
5.
FellowsJRindalDBaraschAGullionCRushWPihlstromD. (2011). ONJ in two dental Practice-based Research Network regions. J Dent Res90:433-438.
6.
KhoslaSBurrDCauleyJDempsterDWEbelingPRFelsenbergD. (2007). Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res22:1479-1491.
7.
RuggieroSLDodsonTBAssaelLALandesbergRMarxREMehrotraB (2009). American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg67(5 Suppl):2S-12S.
8.
Van PoznakC (2006). The phenomenon of osteonecrosis of the jaw in patients with metastatic breast cancer. Cancer Invest24:110-112.
9.
ZahrowskiJJ (2010). Osteonecrosis of the jaws is associated with high-dose bisphosphonate treatment in patients with cancer. J Am Dent Assoc141:887-888.
